Anticoagulation Complications

Supratherapeutic INR, DOAC-associated bleeding, hemorrhage while anticoagulated, and need for reversal

Symptoms / Associated Sx

  • Active bleeding: GI (hematemesis, melena, hematochezia), genitourinary (hematuria), intracranial (headache, neurologic deficits — most feared)

  • Soft tissue/retroperitoneal hematoma: flank pain, groin pain, hemodynamic instability without obvious source

  • Excessive bruising, prolonged bleeding from minor cuts

  • Hemoptysis, epistaxis (less common with DOACs, more common with warfarin)

Denies

  • Recent dose change or missed doses (helps assess if supratherapeutic vs. new bleed without drug change)

  • New medications that interact with warfarin (antibiotics, antifungals, amiodarone, many others — essential to review)

  • Dietary changes (vitamin K intake changes alter warfarin effect)

  • Renal function change (DOAC accumulation with AKI — especially dabigatran)

Social History (SHx)

Indication for anticoagulation (AF, VTE, mechanical valve, APS — guides reversal urgency and restart timing), current anticoagulant type and dose, recent INR values (warfarin), renal function (DOAC dosing), alcohol use (variable warfarin metabolism, GI bleed risk), fall risk, adherence.

Main Etiology

  • Supratherapeutic warfarin: Drug interactions (antibiotics, antifungals, amiodarone, NSAIDs, many others), decreased vitamin K intake (illness, dietary change), acute illness (hepatic), dose error

  • DOAC-associated bleeding: Dose accumulation (AKI — especially dabigatran), drug interactions (P-glycoprotein and CYP3A4 inhibitors), overdose, procedural bleeding

  • Inherent anticoagulation risk: Fall, trauma, procedural bleeding, underlying anatomic lesion (peptic ulcer, AVM, malignancy) unmasked by anticoagulation

Most Common DDx

  • GI bleeding without anticoagulation contribution (underlying lesion — PUD, colon cancer, diverticular bleed — that was present before anticoagulation; EGD/colonoscopy needed regardless of INR)

  • Retroperitoneal hematoma (flank/groin pain + hemodynamic instability on anticoagulation; CT confirms; no obvious external source; urgent reversal + IR/surgical consult)

  • Intracranial hemorrhage (worst complication; headache + neurologic deficits; CT head immediately; emergent reversal regardless of indication)

  • Coagulopathy from liver disease (elevated INR from hepatic synthetic dysfunction, not anticoagulation; check clinical context; LFTs elevated; anticoagulation dose not the cause)

  • DIC (elevated PT/PTT + low fibrinogen + thrombocytopenia + D-dimer — not just elevated INR from warfarin; treat underlying cause)

  • Vitamin K deficiency (malabsorption, poor diet, prolonged antibiotics — mimics supratherapeutic warfarin; not on warfarin; correct with vitamin K supplementation)

DATA

  • PT/INR (warfarin monitoring; NOT reliable for DOACs)

  • PTT (heparin/UFH monitoring; elevated with dabigatran)

  • Anti-Xa level (LMWH, apixaban, rivaroxaban — specialized assay; useful in pregnancy, extremes of weight, renal failure)

  • Thrombin time or Ecarin clotting time (dabigatran level — not universally available)

  • CBC (Hgb drop, platelet count)

  • BMP (creatinine — DOAC accumulation risk; especially dabigatran)

  • LFTs (hepatic metabolism of anticoagulants)

  • CT head non-contrast (if any neurologic symptoms or head trauma)

  • Drug level or timing of last dose (DOACs — helps guide reversal need)

Home Meds

  • Current anticoagulant type, dose, and last dose taken

  • Warfarin interactions: antibiotics (especially fluconazole, metronidazole, fluoroquinolones), amiodarone, NSAIDs, statins, antiepileptics — always review

  • DOAC interactions: P-gp inhibitors (dronedarone, azithromycin, rifampin), CYP3A4 inhibitors/inducers

Plan

  • Supratherapeutic INR (warfarin) — no active bleeding:

    • INR 4–10, no bleeding: Hold warfarin 1–2 doses; recheck INR; restart at lower dose when therapeutic

    • INR >10, no bleeding: Vitamin K 2.5–5 mg PO; hold warfarin; recheck INR in 24–48h

  • Active bleeding on warfarin — reversal:

    • 4-factor PCC (Kcentra): 25 units/kg (INR 2–3.9), 35 units/kg (INR 4–6), 50 units/kg (INR >6); max 5000 units; onset minutes

    • Vitamin K 10 mg IV slow infusion (prevents re-elevation; lasts 6–12h but slow onset 4–6h)

    • FFP 15–30 mL/kg if PCC unavailable (large volumes, slower; risk of volume overload)

    • DO NOT use PCC as sole agent without vitamin K — INR will re-elevate in 6–12h

  • Active bleeding on DOACs — reversal:

    • Dabigatran: Idarucizumab (Praxbind) 5 g IV (two 2.5 g doses) — complete reversal within minutes; approved for life-threatening bleeding or urgent surgery

    • Apixaban/Rivaroxaban: Andexanet alfa (Andexxa) 400 mg IV bolus over 15–30 min → 480 mg IV over 2h (low dose) OR 800 mg IV bolus → 960 mg over 2h (high dose) — based on last dose timing and dose

    • If specific reversal unavailable: 4-factor PCC 50 units/kg IV (off-label — partial reversal of Xa inhibitors)

  • Active bleeding on heparin/LMWH:

    • UFH: Protamine sulfate 1 mg per 100 units heparin IV (max 50 mg; slow infusion); partial reversal of LMWH (1 mg per 1 mg enoxaparin; protamine only ~60% effective for LMWH)

  • For any life-threatening bleed: simultaneous source control (endoscopy, IR, surgery) + reversal agent + transfuse pRBCs if Hgb <7–8 + platelet transfusion if <50k

  • Anticoagulation restart timing:

    • Minor bleeding (epistaxis, small wound): restart within 24–48h

    • GI bleed: 7–10 days after source controlled (discuss with GI)

    • Intracranial hemorrhage: multidisciplinary discussion; typically 4–8 weeks minimum; individualize per thrombosis vs. rebleed risk

    • HIGH-RISK indication (mechanical valve, recent PE, high-risk AF): earlier restart consideration — hematology/cardiology input

  • Trend INR/anti-Xa per anticoagulant type; CBC; BMP; stool guaiac if GI bleed concern

  • Hematology and pharmacy consult for complex reversal decisions

  • PT/OT — fall prevention; bleeding precautions; assisted ambulation

  • Discharge: Anticoagulation restart plan with clear date and indication; INR monitoring schedule (warfarin); patient education on bleeding signs; avoid NSAIDs; fall prevention counseling; PCP and hematology follow-up 1–2 weeks

Red Flags

  • Neurologic symptoms + anticoagulation → intracranial hemorrhage → CT head immediately + urgent reversal regardless of indication

  • Hemodynamic instability + anticoagulated + no obvious source → retroperitoneal hematoma → CT abdomen/pelvis + urgent reversal

  • Mechanical heart valve + need for prolonged anticoagulation hold → valve thrombosis → hematology + cardiac surgery; minimize hold; bridging with UFH

  • INR >10 without bleeding → high imminent bleeding risk → vitamin K 5–10 mg PO + hold warfarin + recheck in 24h

  • AKI + dabigatran → dramatic drug accumulation → check dabigatran level; hold drug; consider idarucizumab if bleeding

Senior IM Resident Pearls

  • INR does NOT reflect DOAC effect — a normal INR does not mean there is no anticoagulant effect from a DOAC; use drug-specific assays (anti-Xa for apixaban/rivaroxaban; thrombin time for dabigatran)

  • PCC alone without vitamin K for warfarin reversal will have INR re-elevate in 6–12h — always give both; vitamin K ensures sustained reversal

  • Andexanet alfa (Andexxa) neutralizes both apixaban and rivaroxaban; however, it shortens anti-Xa activity and may increase thrombosis risk — restart anticoagulation as soon as safely possible

  • Idarucizumab (Praxbind) is the only FDA-approved specific reversal agent for dabigatran — complete reversal within 5 minutes; dialysis also removes dabigatran if agent unavailable

  • Common mistake: Using FFP as first-line for urgent warfarin reversal — FFP is 15–30 mL/kg (massive volume), slow to work, and inferior to 4-factor PCC; PCC is far superior and should be used first when available

  • Common mistake: Permanently stopping anticoagulation after bleeding without reassessing indication — thromboembolic risk (stroke in AF, mechanical valve thrombosis) often exceeds rebleeding risk; always make a documented plan for restart

Anticoagulation Reversal

One-Line Memory Pearls

Warfarin
→ Vitamin K + PCC

Apixaban/Rivaroxaban
→ Andexanet → PCC if unavailable

Dabigatran
→ Idarucizumab (Praxbind)

UFH
→ Protamine 1 mg per 100 units

LMWH
→ Protamine partially reverses (~60–75%)

Argatroban/Bivalirudin
→ Stop infusion

Life-threatening bleed on any anticoagulant
→ Hold anticoagulant + reverse immediately + source control + transfuse as needed (PRBC, platelets, cryo, FFP).

WARFARIN (COUMADIN)

• Vitamin K 10 mg IV x1 (slow infusion over 10–30 min)

• PCC (Kcentra) 25–50 units/kg IV (max 5000 units)

Practical PCC dosing:

- Non-ICH: 1500–2000 units

- ICH: 2000–2500 units

If PCC unavailable:

- FFP 10–15 mL/kg (~4 units)

Monitoring:

- Check INR 30 min after PCC

- Then q6h x24 hr

- Redose PCC +500 units if INR >1.5 or ongoing bleeding

---------------------------------------------------------

FACTOR Xa INHIBITORS

(Apixaban/Eliquis, Rivaroxaban/Xarelto, Edoxaban)

Preferred: Andexanet Alfa (Andexxa)

LOW DOSE:

• 400 mg IV bolus

• Then 480 mg infusion over 2 hr

Use if:

- Apixaban ≤5 mg and >8 hr since last dose

- Rivaroxaban ≤10 mg and >8 hr since last dose

HIGH DOSE:

• 800 mg IV bolus

• Then 960 mg infusion over 2 hr

Use if:

- Apixaban >5 mg

- Rivaroxaban >10 mg

- Unknown dose

- Last dose <8 hr

If Andexanet unavailable:

• PCC (Kcentra) 50 units/kg IV

OR

• PCC 2000 units IV (fixed dose)

---------------------------------------------------------

DABIGATRAN (PRADAXA)

Specific antidote:

• Idarucizumab (Praxbind) 5 g IV

= 2 consecutive 2.5 g IV doses

Additional:

• Activated charcoal if ingestion <2 hr

• Consider repeat dose only if recurrent bleeding + elevated aPTT

---------------------------------------------------------

UNFRACTIONATED HEPARIN (UFH)

Protamine Sulfate (max 50 mg)

0–30 min:

• 1 mg protamine per 100 units heparin

30–60 min:

• 0.75 mg per 100 units

60–120 min:

• 0.5 mg per 100 units

>2 hr:

• 0.25–0.375 mg per 100 units

Administration:

• Slow IV infusion over ≥10 min

Monitoring:

• Repeat aPTT

• May redose if bleeding persists and aPTT remains elevated

---------------------------------------------------------

LOW MOLECULAR WEIGHT HEPARIN (LMWH)

(Enoxaparin/Lovenox)

Partial reversal only (~60–75%)

<8 hr since dose:

• 1 mg protamine per 1 mg enoxaparin

8–12 hr:

• 0.5 mg protamine per 1 mg enoxaparin

>12 hr:

• Usually no reversal needed

Persistent bleeding:

• Additional protamine 0.5 mg per 1 mg enoxaparin

---------------------------------------------------------

DIRECT THROMBIN INHIBITORS (DTI)

Argatroban

Bivalirudin

No antidote

Treatment:

• STOP infusion immediately

Half-life:

• Argatroban ~45 min

• Bivalirudin ~25 min

Supportive care until drug clears

=========================================================

WARFARIN INR MANAGEMENT (NO MAJOR BLEEDING)

=========================================================

INR 4.5–10

No bleeding:

• Hold warfarin

• Usually NO Vitamin K needed

• Consider Vitamin K 1–2.5 mg PO if high bleeding risk

Minor bleeding:

• Hold warfarin

• Vitamin K 1–2.5 mg PO

• Recheck INR in 24 hr

---------------------------------------------------------

INR >10

No bleeding:

• Vitamin K 2.5–5 mg PO

• Recheck INR in 24 hr

Minor bleeding:

• Vitamin K 2.5–5 mg PO

• If unable to take PO:

- Vitamin K 1–5 mg IV

=========================================================

SPECIAL SITUATIONS

=========================================================

Mechanical Valve / LVAD

• Avoid Vitamin K unless necessary

• PCC preferred for urgent reversal

Intracranial Hemorrhage (ICH)

• Do NOT wait for INR result

• Immediate PCC + Vitamin K

• Target INR <1.5